#ESMO16: Boehringer drug flops on OS endpoint; Medivir reorganizes, cuts staff
Fresh on the heels of an embarrassing setback with a lethal cancer drug in-licensed from Hanmi, Boehringer Ingelheim reported over the weekend that nintedanib flunked the co-primary endpoint for overall survival in treating metastatic colorectal cancer. The drug arm did beat out best supportive care for reducing the risk of progression. Boehringer execs say they’re still studying the data, which was reviewed at ESMO.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.